Advances in the hospital management of hyperglycemia and type 2 diabetes in non-critical care settings
Study context
- Population
- Non-critically ill hospitalized adults with hyperglycemia, with and without diabetes
- Outcome
- Contemporary approaches to inpatient hyperglycemia management
Main finding
As reported in the abstract
- Current guidelines recommend individualized therapy targeting blood glucose concentrations of 100-180 mg/dL for most non-critically ill hospitalized patients
- Insulin remains the cornerstone of treatment
- Basal-bolus insulin regimens are preferred for patients with adequate nutritional intake; basal insulin with correction doses may offer a simpler, effective option for selected patients with mild hyperglycemia or reduced oral intake
- Dipeptidyl peptidase-4 inhibitors have an excellent safety profile and, in a randomized trial, served as a good alternative or supplement to basal-bolus insulin in patients with mild hyperglycemia
- Sodium-glucose cotransporter-2 inhibitors are advised for patients with heart failure during hospital stays or soon after discharge
- Continuous glucose monitoring provides a more comprehensive assessment of glucose patterns than intermittent point-of-care testing, facilitates recognition of nocturnal and asymptomatic hypoglycemia, and enables remote glucose monitoring
- Substantial gaps remain between evidence-based recommendations and routine clinical practice
Original publication
Advances in the hospital management of hyperglycemia and type 2 diabetes in non-critical care settings. BMJ Open Diabetes Res Care. Published 9 November 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →